Avalo Therapeutics AVTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $50.09M+105% | $24.44M+77.3% | $13.78M-56.0% | $31.31M-47.7% | ||
| $22.9M+32.8% | $17.24M+67.4% | $10.3M— | —— | ||
| $72.98M+5.8% | $68.96M+136% | $29.28M-47.2% | $55.49M-36.6% | ||
| -$72.93M-6.4% | -$68.51M-151% | -$27.35M+27.0% | -$37.44M+54.4% | ||
| $4.35M+31.3% | $3.31M+195% | -$3.5M+16.1% | -$4.17M-74.4% | ||
| —— | —— | -$4.18M+0.2% | -$4.19M-73.8% | ||
| -$78.09M-123% | -$35.02M-11.1% | -$31.53M+24.3% | -$41.63M— | ||
| $165K+44.7% | $114K— | —— | $27K+114% | ||
| -$78.26M-123% | -$35.13M-11.4% | -$31.54M+24.3% | -$41.66M+50.6% | ||
| -$5.73— | —— | —— | -$1,063.00— | ||
| -$72.58M-6.2% | -$68.35M-151% | -$27.19M+27.1% | -$37.28M+53.7% | ||
| -$72.93M-6.4% | -$68.51M-151% | -$27.35M+27.0% | -$37.44M+54.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Avalo Therapeutics's revenue?
- Avalo Therapeutics (AVTX) generated $500.0K in revenue over the trailing twelve months, down 38.0% year over year.
- Is Avalo Therapeutics profitable?
- Avalo Therapeutics is not currently profitable: it reported a net loss of $84.7M over the trailing twelve months, a -7965.8% net margin.
- What are Avalo Therapeutics's profit margins?
- Gross margin is 182.0% and operating margin is -15536.1%, with a -7965.8% net margin.
- What is Avalo Therapeutics's earnings per share?
- Avalo Therapeutics's diluted EPS over the trailing twelve months is $-5.46.
- Where does Avalo Therapeutics's income statement data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
